ReviewCurrent osteoporosis reports2026
Metabolism in Tumour-Induced Bone Disease.
Review in Current osteoporosis reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review highlights recent studies that investigate the metabolic reprogramming that occurs in specific types of bone metastatic cancers, including different types of breast cancer, prostate cancer and multiple myeloma. RECENT
findingsMetastatic cancer cells use altered metabolic pathways to adapt in alternate environments. Cancer cells that home towards the bone are able to manipulate their metabolism to survive in the hypoxic microenvironment, shifting between oxidative phosphorylation and glycolysis, whilst also exploiting neighbouring cells within the bone to provide energy and protect against chemotherapies. Targeting the altered metabolic pathways in cancer cells could be used to improve treatments, reduce tumour burden and prevent the destruction of the bone that occurs in tumour-induced bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.